UHS: the market is pricing a 2028 Medicaid cut as permanent, and you're getting the hospital business for almost free

**TL;DR:** UHS is the cheapest large US hospital operator (7.6x forward) because the market is treating one 2028 Medicaid change as a permanent hit. I think it's partial, and on peer multiples the behavioural segment alone is worth close to the whole company, so you are paying almost nothing for the hospitals. Fair value \~$282 vs $172 (Buy, high uncertainty). The real risk is that estimates are still falling, which I have put on the record as a kill criterion.

UHS runs two businesses: Acute Care (general hospitals, \~57% of revenue) and Behavioural Health (inpatient psychiatric, \~43%, at roughly twice the margin). FY2025 revenue was $17.4bn. It is investment-grade and cash-generative, yet it trades at 7.6x forward earnings and \~5.9x EV/EBITDA while peers (HCA, Tenet, Acadia, Encompass) sit at 14-20x. The only question is whether the discount is deserved.

**Why it's cheap.** One fear: the 2028 Medicaid state-directed-payment (SDP) step-down. SDPs are supplemental Medicaid payments to hospitals, and a 2025 federal law phases the grandfathered ones down from January 2028. UHS earns about $450m from them, \~17% of the group, so the worry is real. The market has decided the hit is permanent and near-total, and repriced the whole company around it.

I think it is partial. About $90m is protected outright, $360m is exposed, and states keep ways to preserve a share; my base case assumes a 40% floor, fading the payments to \~$234m, not zero. Even if the entire exposed $360m vanished forever from 2028, the cash flows still support a value above today's $172. The market is not pricing the cut. It is pricing the cut plus a permanent penalty on everything else, discounting the cash flows at \~10.7% when the cost of capital is 6.9%.

**The part nobody is paying for.** Behavioural Health earns \~19.7% margins on $7.4bn of revenue. On Acadia's multiple (9.6x EV/EBITDA, and Acadia is itself distressed) that segment alone is worth \~$17bn. UHS's entire enterprise value is $15.8bn. So the behavioural business is worth more than the whole company, and you are getting the larger hospital business for close to nothing; my sum-of-parts gets to $245 a share. The catch: the founding family controls the votes (\~17% insider), so no spin, sale or activist forces the gap shut. I am not betting it closes, only that it is too wide.

**Is it a value trap?** Fair question, because cheap plus falling estimates is what a trap looks like, and UHS's FY2027 consensus has dropped from \~$25.44 to $24.15 in ninety days. So I will be blunt: the thesis needs the cuts to stop, and I have written the line in advance. If FY2027 consensus falls below \~$22 by Q1 2027 without the Medicaid picture clearing, I am wrong on timing and downgrade to Hold. What stops it being a classic trap is quality: ROIC \~12.7% against a 6.9% cost of capital, clean balance sheet, unadorned accounting. Cheapest facility stock, some of the best returns in the group.

**Valuation.** A DCF at 6.9% gets $332; Medicaid-adjusted comps get $232; equal-weight gives \~$282, about 64% above $172, with a bear/base/bull of $220 / $332 / $434.

I publish every call with a fair value, a written kill criterion and a public scorecard I do not edit after the fact. This opens the UHS record at $171.66 / $282 / Buy / 28 August 2026.

Not investment advice, educational research, my own write-up. I hold no position in UHS. Happy to argue the bear side; the SDP retention number is where I would push first.